Clinical Trial: Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Breast Cancer
Study Type: INTERVENTIONAL
Official Title: Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Brief Summary:
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Read more